Skip to Main Content


Yale Department of Endocrine/General Surgery
Yale researchers have introduced countless medical and health advances over the last century, including the first success with antibiotics in the United States and the first use of chemotherapy to treat cancer. University scientists have been responsible for the identification of Lyme disease and the discovery of genes responsible for high blood pressure, osteoporosis, dyslexia, and Tourette's syndrome, among other disorders. Early work on the artificial heart and the creation of the first insulin pump took place at Yale, as did seminal discoveries about how the cell and its components function at the molecular level. Today, research activities take place in a wide range of departments, programs, and centers.

As of fiscal year 2013 Yale research has had 1,815 awards totaling $510.4 million, 416 U.S. and 704 worldwide active patents for Yale inventions, and 58 Yale-founded biotech companies.

The School of Medicine has extraordinary strength in the basic sciences and consistently ranks in the top handful of medical schools receiving funding from the National Institutes of Health.

The section of Endocrine Surgery has strong teaching, research and clinical missions at its foundation. The faculty is composed of active clinical surgeons involved in a busy surgical practice who are dedicated to pursuing clinical, translational, basic science research, as well as to developing new teaching modalities in the field of endocrine surgery. The section has strong multidisciplinary clinical and research collaboration with the departments of Medical Endocrinology, Pathology, Radiology and Genetics within the Yale School of Medicine. The faculty also has multi-institutional research collaborations with many prominent institutions nationally (e.g. National Institute of Health) and internationally (e.g. Uppsala University, Sweden). The section runs a fully funded Yale Endocrine Neoplasia Laboratory.

The surgical clinical volume has risen significantly over the last few years, as referrals of patients with complex endocrine and oncologic problems have increased. This increase in the number and complexity of cases has placed our section on the world map in cutting-edge international clinical trials for advanced or metastatic thyroid cancer, thus offering new therapies and hope for patients who, until now, would have had no good options for treatment.

For more information about the ongoing research in our section, please go to

Grant Support

Tobias Carling, M.D., Ph.D 
Title: Endocrine Cancers - Characterization of Molecular Pathogenesis via Genome Wide Studies
Funding Agency: Gilead-Yale Collaboration
Role: PI
Date: 10/1/2011-9/30/2013
Status: Approved

Tobias Carling, M.D., Ph.D  
Title: Molecular Genetics of Endocrine Tumor Disease
Funding Agency: The Damon Runyon Cancer Research Foundation; Damon Runyon Clinical Investigator Award
Role: PI
Date: 7/1/2010-6/30/2013
Status: Approved. Jointly funded with the Doris Duke Charitable Foundation

Tobias Carling, M.D., Ph.D 
Title: Systematic Analysis of Human Endocrine Tumors
Funding Agency: The Doris Duke Charitable Foundation; Clinical Scientist Development Award
Role: PI
Date: 7/1/2010-6/30/2013
Status: Approved. Jointly funded with the Damon Runyon Cancer Research Foundation 

Tobias Carling, M.D., Ph.D
Title: Molecular Pathogenesis of Benign and Malignant Adrenocortical Tumors
Funding Agency: OHSE Grant Foundation
Role: Supervisor to J. Kunstman, MD

YENL is uniquely positioned to become an international leader in the scientific studies of endocrine tumors.